obesity

News

GLP-1 bonanza spurs big investment at CDMO CordenPharma

CordenPharma has launched a €900 million ($981 million) investment programme to prepare for an expected surge in demand for peptide production capacity – driven by GLP-1 receptor agonists.

News

Pfizer selects once-daily GLP-1 for its obesity push

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate.

R&D

A spectrum of obesity requires precision

Obesity is a hot topic, and a focal research area, in the twentieth century.

News

Lilly scores against Novo Nordisk in weight loss contest

There’s no data from a head-to-head trial directly comparing Eli Lilly and Novo Nordisk’s GLP-1 agonist drugs yet, but an observational study has found that Lilly’s tirzepatide seems to be

News

Study finds GLP-1 drugs may cut obesity-related cancers

Potentially adding to a lengthening list of positive health benefits of GLP-1 agonist drugs, a new study has suggested they may also reduce the risk of a bevy of cancers associated with bei

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

GLP-1 bonanza spurs big investment at CDMO CordenPharma

Pfizer selects once-daily GLP-1 for its obesity push

A spectrum of obesity requires precision

Lilly scores against Novo Nordisk in weight loss contest

Study finds GLP-1 drugs may cut obesity-related cancers

Study links Ozempic/Wegovy to sight-threatening disorder

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

obesity

Editor's Picks